ArticlemedRxiv : the preprint server for health sciences2026
Sensitive periods for prenatal alcohol exposure shape internalizing symptoms across development.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Importance: Prenatal alcohol exposure (PAE) is associated with lasting cognitive and neurodevelopmental deficits and can quadruple risk for depression later in life. However, it remains unknown whether there are specific trimesters when PAE is more strongly associated with longitudinal trajectories of internalizing symptoms - an indicator of depression risk - across childhood and adolescence. Objective: To investigate how PAE timing and dosage are associated with internalizing symptom trajectories from ages 4 to 16.5 years. Design Setting and Participants: We analyzed prospective data from the Avon Longitudinal Study of Parents and Children (ALSPAC), an ongoing longitudinal birth cohort from the United Kingdom. Internalizing symptom trajectories were estimated for 6,409 participants. Primary analyses were conducted on 2,254 participants with complete data on PAE in all three trimesters, covariates, and trajectories. Main Outcomes and Measures: We used growth mixture modelling to identify latent trajectories of depressive symptoms measured using the internalizing symptom scale from the Strengths and Difficulties Questionnaire (SDQ) at seven occasions between ages 4 to 16.5 years. Prospective alcohol consumption during each trimester were categorized into three PAE dosages: unexposed (0 drinks/week), low (1-7 drinks/week) and high (7+ drinks/week). Results: We identified five distinct depressive symptom trajectories: stable low (75.9% of participants), moderate childhood peak (11.2%), progressive increase (5.57%), high early childhood (4.73%), and early adolescent peak (2.61%). PAE in the second (relative risk [RR]=2.08, 95% CI=1.15-3.76) and third trimesters (RR=1.83, 95% CI=1.05-3.21), as well as total PAE burden across pregnancy (RR=1.33, 95% CI=1.06-1.68) increased risk for the progressive increase trajectory, versus the stable low trajectory. High PAE in the second (RR=2.71, 95% CI=1.41-5.21) and third (RR=2.27, 95% CI=1.27-4.05) trimesters drove elevated risk for this trajectory. PAE in the first trimester or at low dosages showed no associations with depressive symptom trajectories. Negative control analyses of paternal drinking also found no associations. Conclusions and Relevance: Our results highlight the second and third trimesters as potential sensitive periods for the impact of PAE on rising depressive symptoms from childhood to adolescence. Ultimately, these findings could inform the design of prevention programs, and facilitate targeted interventions to youth at elevated risk for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.